Incidence and Survival by Human Epidermal Growth Factor Receptor-2 Status in Young Women with Stage I-III Breast Cancer: SEER 2010–2016
| Autor: | Lacey R. McNally, Jacob Oleson, Kristin M Conway, William G Hundley, Anthony Rhoads, Charles F. Lynch, Alexandra Thomas, Susan A. Melin, Paul A. Romitti, Jonathan Suhl |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Cancer Research medicine.medical_specialty Receptor ErbB-2 Breast Neoplasms Kaplan-Meier Estimate Article 03 medical and health sciences Young Adult 0302 clinical medicine Breast cancer Internal medicine Epidemiology medicine Biomarkers Tumor Humans Breast Stage (cooking) skin and connective tissue diseases Human Epidermal Growth Factor Receptor 2 Survival analysis Neoplasm Staging Retrospective Studies business.industry Incidence (epidemiology) Incidence Cancer Middle Aged medicine.disease Prognosis United States 030104 developmental biology Oncology Premenopause Receptors Estrogen Hormone receptor 030220 oncology & carcinogenesis Female business Receptors Progesterone SEER Program |
| Zdroj: | Clin Breast Cancer |
| Popis: | Background Young premenopausal women with breast cancer often experience more aggressive disease biology and poorer survival than older women. Diagnostic and therapeutic advances, including human epidermal growth factor receptor 2 (HER2)-directed therapy, may lessen treatment burden and improve survival for these young women, but contemporary incidence and survival data by HER2 status are limited. Patients and Methods We identified women aged 20-49 years (n = 68,530) diagnosed with stage I-III breast cancer during 2010-2016 from the United States Surveillance, Epidemiology, and End Results 18 registries database. Age-adjusted average annual percent changes in incidence (diagnosis 2010-2016) and 5-year Kaplan-Meier survival curves (diagnosis 2010-2015) were estimated by HER2 and hormone receptor (HR) status and stratified independently by cancer stage and race/ethnicity. Results With increasing age decade, proportions of HER2−/HR+ cancer increased, whereas proportions of HER2+/HR+, HER2+/HR−, and HER2−/HR− decreased. The greatest increases in incidence during 2010-2016 were observed for HER2+ among women aged 20-49 years and HER2−/HR− among women aged 20-29 years. Incidence decreased for HER2−/HR− among women aged 40-49 years. Five-year survival was lowest for HER2−/HR− status compared to other receptor-based subtypes among women aged 20-49 years. HER2+ status was more beneficial for 5-year survival than HR+ status among women aged 20-29 years, with the opposite observed among women aged 30-49 years, particularly those aged 40-49 years. Conclusion HER2+ breast cancer increased among premenopausal women and was also associated with higher early survival within each HR status. HER2−/HR− cancer also increased among women aged 20-29 years and was associated with lower early survival. Our contemporary data provide important insights to help inform preventive and therapeutic strategies for premenopausal women. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|